VKTX vs. LEGN, CERE, ELAN, ASND, JAZZ, ITCI, ROIV, BPMC, CYTK, and CTLT
Should you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Legend Biotech (LEGN), Cerevel Therapeutics (CERE), Elanco Animal Health (ELAN), Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Blueprint Medicines (BPMC), Cytokinetics (CYTK), and Catalent (CTLT). These companies are all part of the "pharmaceutical preparations" industry.
Viking Therapeutics (NASDAQ:VKTX) and Legend Biotech (NASDAQ:LEGN) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, community ranking, risk and media sentiment.
Viking Therapeutics has higher earnings, but lower revenue than Legend Biotech. Viking Therapeutics is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.
Viking Therapeutics received 540 more outperform votes than Legend Biotech when rated by MarketBeat users. Likewise, 79.87% of users gave Viking Therapeutics an outperform vote while only 64.13% of users gave Legend Biotech an outperform vote.
In the previous week, Legend Biotech had 8 more articles in the media than Viking Therapeutics. MarketBeat recorded 29 mentions for Legend Biotech and 21 mentions for Viking Therapeutics. Legend Biotech's average media sentiment score of 0.54 beat Viking Therapeutics' score of 0.50 indicating that Legend Biotech is being referred to more favorably in the news media.
Viking Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -135.92%. Viking Therapeutics' return on equity of -18.41% beat Legend Biotech's return on equity.
Viking Therapeutics currently has a consensus price target of $112.38, indicating a potential upside of 67.72%. Legend Biotech has a consensus price target of $82.74, indicating a potential upside of 83.21%. Given Legend Biotech's higher probable upside, analysts plainly believe Legend Biotech is more favorable than Viking Therapeutics.
76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 4.7% of Viking Therapeutics shares are held by insiders. Comparatively, 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Viking Therapeutics has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500.
Summary
Viking Therapeutics beats Legend Biotech on 12 of the 18 factors compared between the two stocks.
Get Viking Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viking Therapeutics Competitors List
Related Companies and Tools
